Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - San Antonio (Murphy)
mi
from
San Antonio, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - San Antonio (Murphy)
mi
from
San Antonio, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Temple
mi
from
Temple, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Temple
mi
from
Temple, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
CCOP - Scott and White Hospital
mi
from
Temple, TX
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
CCOP - Scott and White Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Salt Lake City
mi
from
Salt Lake City, UT
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Salt Lake City
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Veterans Affairs Medical Center - Seattle
mi
from
Seattle, WA
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Veterans Affairs Medical Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
Puget Sound Oncology Consortium
mi
from
Seattle, WA
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
Puget Sound Oncology Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/23/2015
CCOP - Northwest
mi
from
Tacoma, WA
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/23/2015
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
Improving Fecal Occult Blood Test Completion Rates Among Veterans
Improving Fecal Occult Blood Test Completion Rates Among Veterans
Status: Enrolling
Updated:  10/23/2015
Philadelphia Veterans Affairs Medical Center
mi
from
Philadelphia, PA
Improving Fecal Occult Blood Test Completion Rates Among Veterans
Improving Fecal Occult Blood Test Completion Rates Among Veterans
Status: Enrolling
Updated: 10/23/2015
Philadelphia Veterans Affairs Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Phase II Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Enrolling
Updated:  10/24/2015
University of Southern California (U.S.C.)/ Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Phase II Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Enrolling
Updated: 10/24/2015
University of Southern California (U.S.C.)/ Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated:  10/24/2015
Westside Prostate Cancer Center, University of Southern California
mi
from
Beverly Hills, CA
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated: 10/24/2015
Westside Prostate Cancer Center, University of Southern California
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated:  10/24/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated: 10/24/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Phase II Study of Sunitinib in Patients With Metastatic Papillary Renal Cell Carcinoma
Status: Enrolling
Updated:  10/26/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Phase II Study of Sunitinib in Patients With Metastatic Papillary Renal Cell Carcinoma
Status: Enrolling
Updated: 10/26/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Lung Cancer Symptom Assessment and Management Intervention
Lung Cancer Symptom Assessment and Management Intervention
Status: Enrolling
Updated:  10/26/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Lung Cancer Symptom Assessment and Management Intervention
Lung Cancer Symptom Assessment and Management Intervention
Status: Enrolling
Updated: 10/26/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Lung Cancer Symptom Assessment and Management Intervention
Lung Cancer Symptom Assessment and Management Intervention
Status: Enrolling
Updated:  10/26/2015
Boston Med Ctr
mi
from
Boston, MA
Lung Cancer Symptom Assessment and Management Intervention
Lung Cancer Symptom Assessment and Management Intervention
Status: Enrolling
Updated: 10/26/2015
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Status: Enrolling
Updated:  10/26/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Status: Enrolling
Updated: 10/26/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Status: Enrolling
Updated:  10/26/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Status: Enrolling
Updated: 10/26/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Status: Enrolling
Updated:  10/26/2015
Bellevue Hospital Center (NYU Langone Medical Center affiliate)
mi
from
New York, NY
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Status: Enrolling
Updated: 10/26/2015
Bellevue Hospital Center (NYU Langone Medical Center affiliate)
mi
from
New York, NY
Click here to add this to my saved trials
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12
Status: Enrolling
Updated:  10/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
Phase I/II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Tumor Infiltrating Lymphocytes Genetically Engineered to Express IL-12
Status: Enrolling
Updated: 10/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated:  10/26/2015
Christiana Care Health Services, Inc
mi
from
Newark, DE
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies
Status: Enrolling
Updated: 10/26/2015
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
Newark, DE
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
Newark, DE
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
Duarte, CA
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
Duarte, CA
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
Tampa, FL
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
Tampa, FL
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
Baltimore, MD
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
Baltimore, MD
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
St. Louis, MO
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
New Brunswick, NJ
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
Bronx, NY
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
Bronx, NY
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
Cincinnati, OH
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
Cleveland, OH
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
Hershey, PA
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
Hershey, PA
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
Philadelphia, PA
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
Nashville, TN
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
Nashville, TN
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
San Antonio, TX
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated:  10/26/2015
Local Institution
mi
from
Montreal,
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Status: Enrolling
Updated: 10/26/2015
Local Institution
mi
from
Montreal,
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Los Angeles, CA
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Roseville, CA
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Roseville, CA
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Tampa, FL
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
New Orleans, LA
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
St. Louis, MO
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Las Vegas, NV
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
mi
from
Liverpool,
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
mi
from
Liverpool,
Click here to add this to my saved trials
Optimizing Navigation to Successful Colorectal Cancer Screening
Optimizing Navigation to Successful Colorectal Cancer Screening
Status: Enrolling
Updated:  10/26/2015
Rush University Medical Center
mi
from
Chicago, IL
Optimizing Navigation to Successful Colorectal Cancer Screening
Optimizing Navigation to Successful Colorectal Cancer Screening
Status: Enrolling
Updated: 10/26/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Status: Enrolling
Updated:  10/26/2015
Jackson Health System
mi
from
Miami, FL
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Status: Enrolling
Updated: 10/26/2015
Jackson Health System
mi
from
Miami, FL
Click here to add this to my saved trials
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Status: Enrolling
Updated:  10/26/2015
University of Miami
mi
from
Miami, FL
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Facilitating Adjustment in Low Income Black Women With Breast Cancer
Status: Enrolling
Updated: 10/26/2015
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Oxaliplatin and Topotecan in Advance Ovarian Cancer
A Phase II Study of Oxaliplatin Combined With Continuous Infusion Topotecan as Chemotherapy for Patients With Previously Treated Ovarian Cancer
Status: Enrolling
Updated:  10/27/2015
Montefiore Medical Center
mi
from
Bronx, NY
Oxaliplatin and Topotecan in Advance Ovarian Cancer
A Phase II Study of Oxaliplatin Combined With Continuous Infusion Topotecan as Chemotherapy for Patients With Previously Treated Ovarian Cancer
Status: Enrolling
Updated: 10/27/2015
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Oxaliplatin and Topotecan in Advance Ovarian Cancer
A Phase II Study of Oxaliplatin Combined With Continuous Infusion Topotecan as Chemotherapy for Patients With Previously Treated Ovarian Cancer
Status: Enrolling
Updated:  10/27/2015
NYU Cancer Institute
mi
from
New York, NY
Oxaliplatin and Topotecan in Advance Ovarian Cancer
A Phase II Study of Oxaliplatin Combined With Continuous Infusion Topotecan as Chemotherapy for Patients With Previously Treated Ovarian Cancer
Status: Enrolling
Updated: 10/27/2015
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status: Enrolling
Updated:  10/27/2015
Clinical Research Facility
mi
from
Houston, TX
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status: Enrolling
Updated: 10/27/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials